对范德普吕伊姆等人的回复。对“Weitzman等人。对抗疟单一疗法的耐药性是周期性的。2022年，，781”的评论。
Reply to van der Pluijm et al. Comment on "Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. 2022, , 781".
作者信息
Calfon-Peretz Ortal, Weitzman Rachel, Amitay Moshe, Samson Abraham O
机构信息
Bioinformatic Department, Jerusalem College of Technology, Jerusalem 9372115, Israel.
Drug Discovery Lab, Azrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
出版信息
J Clin Med. 2022 May 25;11(11):2972. doi: 10.3390/jcm11112972.
Abstract
Thank you for the opportunity to respond to comments gracefully raised by van der Pluijm et al. [...].
摘要
感谢有机会对范德普卢伊姆等人[……]委婉提出的意见作出回应。
相似文献
1
Reply to van der Pluijm et al. Comment on "Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. 2022, , 781".
J Clin Med. 2022 May 25;11(11):2972. doi: 10.3390/jcm11112972.
2
Comment on Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. 2022, , 781.
J Clin Med. 2022 May 23;11(10):2934. doi: 10.3390/jcm11102934.
3
Reply to van der Pluijm et al., "Antimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failures".
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00815-17. Print 2017 Jul.
4
Reply to Weiss, H.-R. Comment on "Costa et al. The Effectiveness of Different Concepts of Bracing in Adolescent Idiopathic Scoliosis (AIS): A Systematic Review and Meta-Analysis. 2021, , 2145".
J Clin Med. 2022 Feb 10;11(4):918. doi: 10.3390/jcm11040918.
5
Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on "Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). 2022, , 5158".
J Clin Med. 2023 Jun 13;12(12):4017. doi: 10.3390/jcm12124017.
6
Reply to Cione et al. Comment on "Moshirfar et al. Accuracy of Six Intraocular Lens Power Calculations in Eyes with Axial Lengths Greater than 28.0 mm. 2022, , 5947".
J Clin Med. 2023 May 4;12(9):3268. doi: 10.3390/jcm12093268.
7
Reply to Spiess, B.D.; Houdijk, W.P.M. Comment on "Saner et al. The Yin and the Yang of Hemostasis in End-Stage Liver Disease. 2023, , 5759".
J Clin Med. 2024 Mar 14;13(6):1668. doi: 10.3390/jcm13061668.
8
Reply to Kielb et al. Untapped Potential for Female Patients? Comment on "Lucà et al. Update on Management of Cardiovascular Diseases in Women. 2022, , 1176".
J Clin Med. 2022 May 30;11(11):3086. doi: 10.3390/jcm11113086.
9
Reply to Ross, K. Comment on "Polak et al. Principles and Limitations of miRNA Purification and Analysis in Whole Blood Collected during Ablation Procedure from Patients with Atrial Fibrillation. 2024, , 1898".
J Clin Med. 2024 Jun 26;13(13):3745. doi: 10.3390/jcm13133745.
10
Reply to Böning et al. Comment on "Ceruti et al. Temporal Changes in the Oxyhemoglobin Dissociation Curve of Critically Ill COVID-19 Patients. 2022, , 788".
J Clin Med. 2022 Aug 4;11(15):4547. doi: 10.3390/jcm11154547.
本文引用的文献
1
Comment on Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. 2022, , 781.
J Clin Med. 2022 May 23;11(10):2934. doi: 10.3390/jcm11102934.
2
Resistance to Antimalarial Monotherapy Is Cyclic.
J Clin Med. 2022 Jan 31;11(3):781. doi: 10.3390/jcm11030781.
3
Global antibiotic resistance is mostly periodic.
J Glob Antimicrob Resist. 2016 Dec;7:132-134. doi: 10.1016/j.jgar.2016.09.003. Epub 2016 Oct 11.
Zotero 插件